Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Improving the economics of NASH/NAFLD treatment through the use of systems biology
KTH, Centres, Science for Life Laboratory, SciLifeLab.
KTH, School of Biotechnology (BIO), Proteomics and Nanobiotechnology. KTH, Centres, Science for Life Laboratory, SciLifeLab.ORCID iD: 0000-0002-6428-5936
Show others and affiliations
2017 (English)In: Drug Discovery Today, ISSN 1359-6446, E-ISSN 1878-5832, Vol. 22, no 10, p. 1532-1538Article, review/survey (Refereed) Published
Abstract [en]

Nonalcoholic steatohepatitis (NASH) is a severe form of nonalcoholic fatty liver disease (NAFLD). We surveyed NASH therapies currently in development, and found a significant variety of targets and approaches. Evaluation and clinical testing of these targets is an expensive and time-consuming process. Systems biology approaches could enable the quantitative evaluation of the likely efficacy and safety of different targets. This motivated our review of recent systems biology studies that focus on the identification of targets and development of effective treatments for NASH. We discuss the potential broader use of genome-scale metabolic models and integrated networks in the validation of drug targets, which could facilitate more productive and efficient drug development decisions for the treatment of NASH.

Place, publisher, year, edition, pages
ELSEVIER SCI LTD , 2017. Vol. 22, no 10, p. 1532-1538
National Category
Pharmacology and Toxicology
Identifiers
URN: urn:nbn:se:kth:diva-217446DOI: 10.1016/j.drudis.2017.07.005ISI: 000413799500008PubMedID: 28736156Scopus ID: 2-s2.0-85026322326OAI: oai:DiVA.org:kth-217446DiVA, id: diva2:1158036
Note

QC 20171117

Available from: 2017-11-17 Created: 2017-11-17 Last updated: 2018-01-13Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMedScopus

Authority records BETA

Lee, SunjaeNielsen, JensUhlén, MathiasMardinoglu, Adil

Search in DiVA

By author/editor
Borén, ChristoferLee, SunjaeNielsen, JensUhlén, MathiasMardinoglu, Adil
By organisation
Science for Life Laboratory, SciLifeLabProteomics and Nanobiotechnology
In the same journal
Drug Discovery Today
Pharmacology and Toxicology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 34 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf